Market Place
Sourcing Support
J&J to Present Neuropsychiatry Innovation at 2025 Psych Congress
15 Sep 2025 //
PR NEWSWIRE
Novartis Falls in Another IRA Price Negotiation Loss for Pharma
12 Sep 2025 //
FIERCE PHARMA
J&J Pursues 1st EMA Approval for Icotrokinra in Plaque Psoriasis
11 Sep 2025 //
GLOBENEWSWIRE
Dr Reddy’s Expands CNS Portfolio With Acquisition of Stugeron
10 Sep 2025 //
PRESS RELEASE
Cullinan, Taiho`s NSCLC Shows `Strong Activity`, Paves Way to FDA
10 Sep 2025 //
BIOSPACE
Ronovo Raises $67M for Surgical Robots with J&J Support
09 Sep 2025 //
FIERCE BIOTECH
US FDA approves J&J`s Bladder Cancer Treatment
09 Sep 2025 //
PRESS RELEASE
Johnson & Johnson Appoints John Morikis to Board of Directors
08 Sep 2025 //
BUSINESSWIRE
Johnson & Johnson to Join Bernstein`s 2nd Annual Healthcare Forum
08 Sep 2025 //
BUSINESSWIRE
AstraZeneca Strengthens Tagrisso`s Position Against J&J Rivalry
08 Sep 2025 //
FIERCE PHARMA
RYBREVANT & LAZCLUZE May Improve Survival in Lung Cancer
07 Sep 2025 //
GLOBENEWSWIRE
J&J`s Imaavy Comes up Short in Rheumatoid Arthritis Study
02 Sep 2025 //
FIERCE PHARMA
J&J Drops Development of Arthritis Drug After Trial Setback
29 Aug 2025 //
REUTERS
J&J Boosts US Manufacturing Commitment by $2B Amid Tariff Threats
23 Aug 2025 //
BIOSPACE
AZ, Genentech, Merck top oncology HCP promotions: report
14 Aug 2025 //
FIERCE PHARMA
Johnson & Johnson Joins Morgan Stanley`s 23rd Global Conference
30 Jul 2025 //
BUSINESSWIRE
J&J and Legend Launch First Carvykti TV Ad for Multiple Myeloma
30 Jul 2025 //
FIERCE PHARMA
Boston Jury Awards $42M In Johnson Baby Powder Asbestos Case
29 Jul 2025 //
BUSINESSWIRE
J&J files with U.S. FDA to include new evidence in TREMFYA
29 Jul 2025 //
PR NEWSWIRE
Johnson & Johnson to Participate in 2025 Wells Fargo Health Conf
24 Jul 2025 //
BUSINESSWIRE
EU Okays IMBRUVICA for Untreated Mantle Cell Lymphoma
23 Jul 2025 //
GLOBENEWSWIRE
EU Clears DARZALEX for High-Risk Multiple Myeloma Treatment
23 Jul 2025 //
GLOBENEWSWIRE
EU Approves DARZALEX Faspro® for Multiple Myeloma
23 Jul 2025 //
PR NEWSWIRE
Pacira Bio Expands Zilretta Promotion via Strategic Collaboration
22 Jul 2025 //
GLOBENEWSWIRE
J&J Pursues 1st FDA Approval for Icotrokinra in Plaque Psoriasis
21 Jul 2025 //
PR NEWSWIRE
J&J Gets FDA Priority Review For TAR-200 In High-Risk Cancer
18 Jul 2025 //
PR NEWSWIRE
Johnson & Johnson Raises 2025 Outlook After Q2 Results
16 Jul 2025 //
BUSINESSWIRE
Johnson & Johnson Declares Q3 2025 Quarterly Dividend
16 Jul 2025 //
BUSINESSWIRE
Real Chemistry Appoints Three to Catalyze Change
16 Jul 2025 //
FIERCE PHARMA
J&J Records High Innovative Drug Sales Amid Stelara`s Fall
16 Jul 2025 //
FIERCE PHARMA
J&J Raises Outlook Due to Increased Cardiac Device Sales
16 Jul 2025 //
FIERCE BIOTECH
Caplyta`s Fda Application Shows Schizophrenia Relapse Prevention
09 Jul 2025 //
PR NEWSWIRE
J&J Defeats Generic Drugmakers in Appeal Over Schizophrenia Drug
09 Jul 2025 //
REUTERS
J&J seeks EMA approval to expand Akeega
04 Jul 2025 //
GLOBENEWSWIRE
Janssen’s Biologics Stelara Receives Suppl Approval in US
27 Jun 2025 //
FDA
Nipocalimab better than FcRn blockers for gMG in 24-week study
25 Jun 2025 //
GLOBENEWSWIRE
J&J launches AI surgery funding competition with Nvidia, AWS
24 Jun 2025 //
FIERCE BIOTECH
US Babies Lack Key Gut Bacteria Raising Chronic Disease Risk
24 Jun 2025 //
GLOBENEWSWIRE
Nipocalimab Outperforms FcRn Blockers in gMG ITC Study
23 Jun 2025 //
GLOBENEWSWIRE
Imaavy (nipocalimab-aahu) outperforms FcRn blockers in gMG
23 Jun 2025 //
PR NEWSWIRE
CHMP Backs Darzalex for High-Risk Smouldering Myeloma
20 Jun 2025 //
GLOBENEWSWIRE
IMBRUVICA® (ibrutinib) gets CHMP nod for MCL treatment
20 Jun 2025 //
GLOBENEWSWIRE
Talvey and Tecvayli Combo Effective in Multiple Myeloma Patients
15 Jun 2025 //
PR NEWSWIRE
J&J Lymphoma CAR-T hits 100% ORR in 10 patients
13 Jun 2025 //
FIERCE BIOTECH
Clyra Medical Technologies Names Chris Lyon Chief Revenue Officer
13 Jun 2025 //
ACCESSWIRE
IMBRUVICA Combo Shows Edge Over Acalabrutinib in CLL
12 Jun 2025 //
GLOBENEWSWIRE
Tremfya® Inhibits Joint Damage in Psoriatic Arthritis
11 Jun 2025 //
PR NEWSWIRE
Johnson & Johnson Elects Daniel Pinto to Board
10 Jun 2025 //
BUSINESSWIRE
J&J’s Akeega First PARP Combo to Improve HRR-Mutated mHSPC
03 Jun 2025 //
GLOBENEWSWIRE
CARVYKTI® delivers lasting remissions in multiple myeloma
03 Jun 2025 //
GLOBENEWSWIRE
J&J PARP Path Unclear in Prostate Cancer
03 Jun 2025 //
FIERCE PHARMA
ASCO: J&J captures `Breathtaking Moments` at Chicago skyscraper
03 Jun 2025 //
FIERCE PHARMA
Darzalex Subcutaneous Regimen Benefits Newly Diagnosed Myeloma
03 Jun 2025 //
GLOBENEWSWIRE
J&J’s PARP inhibitors Combo Shows Benefit in HRR+ mCSPC
03 Jun 2025 //
PR NEWSWIRE
Johnson & Johnson`s Trispecific Antibody Shows Promise in Myeloma
03 Jun 2025 //
PR NEWSWIRE
Carvykti Infusion Leads to Lasting Remissions in Myeloma
03 Jun 2025 //
PR NEWSWIRE
J&J shares survival data on KLK2 bispecific in prostate cancer
03 Jun 2025 //
FIERCE BIOTECH
J&J Show Early Anti-Tumor Effect Of Pasritamig In Prostate Cancer
01 Jun 2025 //
PR NEWSWIRE
Johnson & Johnson Investor Call on Q2 Results
28 May 2025 //
BUSINESSWIRE
FDA Advisors Back Darzalex as Treatment for Early Myeloma
21 May 2025 //
FIERCE PHARMA
